Hillman Cancer Research Pavilion

Pittsburgh, Pennsylvania 15232

0 studies enrolling now · 2 studies all time

What they study most

Malignant Melanoma, Melanoma, Metastases

Studies at this site

• Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma — Completed
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma — Completed